Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Link
http://link.springer.com/content/pdf/10.1186/s12894-019-0453-9.pdf
Reference15 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. Epub 2017/01/06. doi: https://doi.org/10.3322/caac.21387 . PubMed PMID: 28055103.
2. van Gent DC, Kanaar R. Exploiting DNA repair defects for novel cancer therapies. Mol Biol Cell 2016;27(14):2145–2148. Epub 2016/07/16. doi: https://doi.org/10.1091/mbc.E15-10-0698 . PubMed PMID: 27418635; PubMed Central PMCID: PMCPMC4945134.
3. Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Int J Clin Oncol 2017;22(4):611–618. Epub 2017/05/17. doi: https://doi.org/10.1007/s10147-017-1137-7 . PubMed PMID: 28508305.
4. O'Connor MJ. Targeting the DNA damage response in Cancer. Mol Cell 2015;60(4):547–560. Epub 2015/11/23. doi: https://doi.org/10.1016/j.molcel.2015.10.040 . PubMed PMID: 26590714.
5. Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, et al. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501–1509. Epub 2018/06/09. doi: https://doi.org/10.2147/DDDT.S124447 . PubMed PMID: 29881257; PubMed Central PMCID: PMCPMC5983012.
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?;Current Oncology;2023-08-30
2. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer;Frontiers in Endocrinology;2022-10-03
3. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses;The Oncologist;2022-09-19
4. PARP Inhibitors: A New Horizon for Patients with Prostate Cancer;Biomedicines;2022-06-15
5. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial;The Lancet Oncology;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3